Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Sanofi CEO: mRNA is likely the 'go-to' vaccine tech for a pandemic, but the 'bar is high' in other diseases
Centene launching organizational restructuring effort, will cull 3K employees, 1.5K open jobs
Cancer trials a major victim of pandemic as global studies dropped by 60%: JAMA
India's Cadila saddled with more COVID-19 vaccine orders than it can fill
Highmark expands access to Freespira's digital PTSD, panic disorder therapy
UPDATED Coronavirus tracker: Providence, Lumedic team up to launch digital COVID vaccine cards
Veru's COVID-19 drug hopeful scrapes efficacy hurdle, but questions remain
Tiziana posts clinical COVID-19 data on nasal antibody delivery

Featured Story

Sanofi CEO: mRNA is likely the 'go-to' vaccine tech for a pandemic, but the 'bar is high' in other diseases

By Eric Sagonowsky

In the global COVID-19 vaccine race, mRNA vaccines quickly got out to the front of the pack and two reached distribution in less than a year. But their quick success in COVID-19 doesn't guarantee mRNA will replace traditional vaccine technologies across the industry, Sanofi CEO Paul Hudson told Barron’s.

Centene launching organizational restructuring effort, will cull 3K employees, 1.5K open jobs

By Paige Minemyer

Centene Corporation posted a $12 million profit loss in the fourth quarter of 2020.

Cancer trials a major victim of pandemic as global studies dropped by 60%: JAMA

By Ben Adams

Data out from Medidata and published by the JAMA network have found oncology tests dropped off dramatically in the first wave of the pandemic last year.

India's Cadila saddled with more COVID-19 vaccine orders than it can fill

By Fraiser Kansteiner

With its shot now entering the phase 3 stretch, India's Cadila has more orders for its plasmid DNA-based COVID-19 vaccine than it can make. The company has a production facility coming online early next year, good for 120 million doses. Meanwhile, it hopes to pick up a manufacturing partner to add 70 million doses.

Highmark expands access to Freespira's digital PTSD, panic disorder therapy

By Paige Minemyer

Highmark is expanding access to Freespira, a digital therapeutic for panic disorder and post-traumatic stress disorder, across its membership.

UPDATED Coronavirus tracker: Providence, Lumedic team up to launch digital COVID vaccine cards

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Veru's COVID-19 drug hopeful scrapes efficacy hurdle, but questions remain

By Ben Adams

Little-known Miami biotech Veru saw its shares jump this week after reporting seemingly positive data from a small phase 2 in COVID-19 patients.

Tiziana posts clinical COVID-19 data on nasal antibody delivery

By Nick Paul Taylor

Tiziana Life Sciences has reported data from a small clinical trial of a nasally administered antibody in COVID-19 patients. The study provided early evidence that the anti-CD3 human monoclonal antibody can improve outcomes in people infected with the pandemic coronavirus.

COVID-19 Tracker